Elicio Therapeutics Inc

ELTXNASDAQ · USD
1.91USD0.00 (+1.06%)
132

Elicio Therapeutics Inc (ELTX) Option Chain

As of September 18, 2026, Elicio Therapeutics Inc is trading at $1.91, a +1.06% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 128.6%. IV Rank is 10%.

Read more

Tracking the ELTX option chain helps you see every strike and expiry on Elicio Therapeutics Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Elicio Therapeutics Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of ELTX options activity at a glance. Use our scanner to monitor the ELTX option chain in real time and filter for the ELTX options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For ELTX stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the ELTX option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where ELTX stock options are being actively traded and where they are not.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers.

The company is headquartered in Boston, Massachusetts.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Elicio Therapeutics Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen ELTX options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of ELTX stock options — let the full option chain come to you, pre-filtered and ready to trade.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile26.98% Subdued
  • Market cap (M$)50
  • 52 weeks high-88.06%
  • 52 weeks low12.35%
  • Analyst recommendationStrong Buy
    1.40
  • Target price$18.90
    889.53% above the current stock price
  • Dividend
  • Payout ratio
  • Earnings date2026-11-12
  • P/E
  • Future P/E
  • EPS (ttm)-2.11
  • EPS growth next 5 years-8.55%

As of September 18, 2026

2026-10-16
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
77.40000.200.000.202.50+32.280.104.300.591.61015522.60
96.651600.550.000.555.00+164.550.705.503.090.01003.35
99.31000.550.000.557.50+296.833.108.005.59-0.04000.69

As of September 18, 2026

Scan the full option chain in one place

Browse the full ELTX option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.

Start your 14-day free trial